Physician profile
Joshua Steele
NPI 1366946303
$4,436.66
in general payments reported to CMS, 2019-2025
25 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $243 · 2023: $680 · 2024: $1,802 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,092.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.22 | 2022-2025 | Linzess, Rinvoq |
| Janssen Biotech, INC. | $793.37 | 2024-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $434.33 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $256.16 | 2023-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $239.28 | 2023-2025 | Livdelzi, Epclusa |
| Ardelyx, INC. | $202.56 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $149.33 | 2022-2025 | |
| Pfizer INC. | $136.62 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.57 | 2022-2024 | Xifaxan, Plenvu |
| Genzyme Corporation | $126.00 | 2024 | |
| Celgene Corporation | $100.90 | 2021 | |
| Janssen Scientific Affairs, LLC | $98.36 | 2024 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $94.32 | 2023-2024 | Linzess |
| Smith+Nephew, INC. | $91.26 | 2024 | Pico |
| Exact Sciences Corporation | $86.31 | 2024 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.53 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $25.76 | 2025 | Injectafer |
| Sandoz INC. | $24.17 | 2025 | Hyrimoz |
| Ionis Pharmaceuticals, INC. | $20.52 | 2025 | Tryngolza |
| Madrigal Pharmaceuticals | $19.12 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $17.78 | 2023 | Dificid |
| Medtronic, INC. | $17.72 | 2025 | Pillcam |
| Nestle Healthcare Nutrition INC. | $16.41 | 2022 | |
| Novo Nordisk INC | $15.13 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $10.93 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.